Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Shire reports reduced angiogenic potential of Dynepo

Shire reports reduced angiogenic potential of Dynepo

6th November 2007

Shire has announced new study data showing that Dynepo (epoetin delta) has a reduced angiogenic potential than darbepoetin alfa in vitro at similar pharmacokinetic concentrations.

The trial results, presented to the annual meeting of the American Society of Nephrology in San Francisco, showed the angiogenic properties of epoetin delta derived from human cells and darboepoetin alfa in a number of concentrations using an in vitro model seeking to encompass a number of features of the process of angiogenesis.

Angiogenesis refers to the formation of new blood vessels from pre-existing vessels, a process that plays a vital role in the growth and malignancy of tumours and diabetic retinopathy.

Professor Alan Stitt of the Centre for Vision Science at Queen’s University, Belfast, said: “In the clinical setting, there are situations where reduced angiogenic potential is beneficial, for example, in patients with malignancies or proliferative retinopathy.”

He added that further testing in clinical and non-clinical settings would now be necessary for continued assessment of the angiogenic potential and other molecular mechanisms of the compound.

In March 2007, Shire announced the European launch of Dynepo, with the product released in Germany, starting the roll-out programme for the drug across the continent.

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.